Co-Administration of Suboxone and Clonazepam Should Be Avoided Whenever Possible
Clinicians should avoid prescribing Suboxone (buprenorphine/naloxone) and clonazepam concurrently whenever possible due to increased risk of respiratory depression, overdose, and death 1.
Primary Safety Concerns
The combination of buprenorphine and benzodiazepines like clonazepam creates a dangerous pharmacodynamic interaction that significantly increases mortality and morbidity risk:
Respiratory depression and fatal overdose: The FDA label explicitly warns that deaths have occurred when buprenorphine is combined with benzodiazepines 2. This represents a dangerous combination of CNS depressants that can lead to fatal respiratory depression.
Increased overdose risk: Recent systematic review evidence (2026) demonstrates increased risk of opioid overdose in patients co-using buprenorphine with benzodiazepines, though results for non-fatal overdose are mixed 3.
All-cause mortality: Mixed evidence exists for increased all-cause mortality with buprenorphine-benzodiazepine combinations, with some studies showing elevated risk 3.
Clinical Decision Algorithm
If Patient Is Not Yet on Either Medication:
- Do not initiate both medications simultaneously
- Prioritize treating the opioid use disorder with buprenorphine first
- Use non-benzodiazepine alternatives for anxiety (SSRIs, SNRIs, buspirone, gabapentin, or evidence-based psychotherapy like CBT) 1
If Patient Is Already on Both Medications:
Do not abruptly discontinue either medication - this is critical as benzodiazepine withdrawal can cause seizures, delirium tremens, and rarely death 1
Taper opioids first when possible - it is generally safer and more practical to taper buprenorphine before benzodiazepines 1
If benzodiazepine taper is necessary:
During concurrent use (if unavoidable):
Important Caveats
Limited circumstances where concurrent use may be appropriate: Severe acute pain in a patient on long-term, stable low-dose benzodiazepine therapy 1. However, even in these cases, benefits must clearly outweigh risks.
Prevalence of co-use: Despite guidelines, approximately 1 in 8 buprenorphine prescriptions are used concomitantly with benzodiazepines, and 16-21% of patients on buprenorphine use benzodiazepines 4, 5. This reflects real-world complexity but does not make the practice safe.
Buprenorphine's partial safety advantage: While buprenorphine has a ceiling effect for respiratory depression when used alone 6, this protective effect is substantially diminished when combined with benzodiazepines 2, 7.
Naloxone in overdose: Standard naloxone dosing may not be fully effective in reversing respiratory depression from buprenorphine 2, making prevention of overdose even more critical.
Communication Strategy
- Discuss safety concerns explicitly with patients about increased respiratory depression and overdose risk 1
- Coordinate care between all prescribers - communicate with other clinicians prescribing controlled substances 1
- Check PDMP data before prescribing and periodically during treatment to identify dangerous combinations 1
- Never dismiss patients from care based on concurrent use - this creates missed opportunities for life-saving interventions 1
The evidence consistently demonstrates that while buprenorphine alone has favorable safety compared to full opioid agonists, combining it with clonazepam or other benzodiazepines substantially increases risk of serious adverse outcomes including death.